Remus Pharmaceuticals Ltd. NSE: REMUS

Remus Pharmaceuticals Ltd. Live Share Price Today, Share Analysis and Chart

2043.50 13.50 (0.67%)

27.91% Fall from 52W High

5,200 NSE Volume

NSE 11 Apr, 2025 3:31 PM (IST)

Loading... You have run out of DVM views! Check usage
Subscribe now to see details
Not Eligible
-
Expensive Valuation
6.5 / 100
Technically Neutral
38.9 / 100

Remus Pharma Live Price Chart

Switch to TradingView
Fetching data ...

Remus Pharma Stock Analysis

Remus Pharma stock analysis with key metrics, changes, and trends.

Remus Pharma MetricVALUECHANGE %TRENDANALYSIS
Price to Earning Ratio46.35-negative

Price to Earning Ratio is 46.35, higher than its sector PE ratio of 38.6.

Stock Price₹2043.5039.01%positive

Stock Price rose 39.01% and outperformed its sector by 23.4% in the past year.

Debt to Equity Ratio0.13-positive

Debt to Equity Ratio of 0.13 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE)29.90 %29.9%positive

Return on Equity(ROE) for the last financial year was 29.9%, more than 20% in the last financial year, indicating an efficient use of shareholder's capital to generate profit.

Mutual Fund Holding0.00 %0%neutral

Mutual Fund Holding remained the same in the last quarter at 0%.

Promoter Share Holding70.84 %-neutral

Promoter Share Holding stayed the same in the most recent quarter at 70.84%.

Interest Coverage Ratio68.56-positive

Interest Coverage Ratio is 68.56, higher than 1.5. This means that it is able to meet its interest payments comfortably with its earnings (EBIT).

Promoter Pledges0.00 %-positive

Promoter Pledges are zero.

VIEW LESS


Loading data..

Earnings Conference Calls, Investor Presentations and Annual Reports

No documents available

Remus Pharmaceuticals Ltd. - Company Profile

What does Remus Pharmaceuticals Ltd. do?

Remus Pharmaceuticals is engaged in the business of Marketing and distribution of API and Finished Formulations of Pharmaceutical drugs and Provision for Technical consultancy services in various countries including India.

Website: www.remuspharma.com

Remus Pharmaceuticals Ltd. Management structure

All Gross Remunerations are in INR
Deval Patel
Company Secretary, Compliance Officer
-
2024-3-31
Gross Remuneration
Year
Ms. Anjali Shah
Chief Financial Officer
-
2024-3-31
Gross Remuneration
Year

Remus Pharmaceuticals Ltd. - company history

Remus Pharmaceuticals Limited was originally incorporated as `Remus Pharmaceuticals Private Limited' as a Private Limited Company, vide Certificate of Incorporation dated September 21, 2015, issued by the Assistant Registrar of Companies, Gujarat. Subsequently, Company converted from a Private to Public and the name of the Company was changed to "Remus Pharmaceuticals Limited" on January 06, 2023 by the Registrar of Companies, Ahmedabad. The Company is engaged in marketing & distribution of finished formulations of pharmaceutical drugs. It deals in API (Active Pharmaceutical Ingredient), provide technical consultancy services to various distributors for preparation of reports on the dossiers of the products to be registered by them in various countries. The Company deal in drug forms like Capsules, Cream, Eye Drops, Gel, Infusion, Inhalation, Inhaler, Injection, Nail Lacquer, Nasal Solution, Nasal Spray, Nebuliser, Ointment, Ophthalmic, Oral Gel, Oral Solution, Oral Suspension, Sachet, Suspension, Tablet. The core business of the Company into three categories, which comprise of Manufacturing, through loan licencse or on contract manufacturing bassis, of approved finished formulations and distribution of the same in various countries; Trading of Active Pharmaceutical Ingredients and Technical Consultancy on preparation of reports on pharmaceutical dossiers.The product portfolio comprises of therapeutic drugs like ACE inhibitors, anaesthetic, Anti histamine, Antifungal, Anti-inflammatory, Antibiotic, Antidiabetic, Antipsychotic, Antiretroviral, Chronic Obstructive Pulmonary Disease, Asthma, Carcinoid tumours, CNS stimulants, Nasal decongestants, Potassium deficiency, Probiotic, Antispasmodic, Ocular-hypertension, Urology and Vitamin deficiency. The Pharma business operations are supported by various contract manufacturers having facilities which are WHO GMP Compliant. The core strength lies in getting approved formulation manufactured through contract manufacturers under loan licence and marketing of formulations through marketing network across geographies. The Company incorporated 'Relius Pharmaceuticals SRL' as a new subsidiary Company in Bolivia, effective on October 13, 2023. The Company made an Initial Public Issue of 388000 Equity Shares of face value of Rs 10/- each by raising funds aggregating to Rs 47.68 Crore through Fresh Issue in May, 2023. The Company acquired a majority stake (56.67%) of a USA based company, namely Espee Global Holdings LLC, making it a subsidiary of the Company effective on January 1, 2024.

Remus Pharmaceuticals Ltd. FAQ

How is Remus Pharmaceuticals Ltd. today?
Remus Pharmaceuticals Ltd. today is trading in the green, and is up by 0.67% at 2043.50.
Remus Pharmaceuticals Ltd. is currently trading up 0.67% on an intraday basis. In the past week the stock fell -5.23%. stock has been down -11.77% in the past quarter and rose 39.01% in the past year. You can view this in the overview section.